Network analysis reveals distinct clinical syndromes underlying acute mountain sickness

Citation for published version:

Digital Object Identifier (DOI):
10.1371/journal.pone.0081229

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS One

Publisher Rights Statement:
Copyright: © 2014 Hall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness

David P. Hall1,2, Ian J. C. MacCormick2, Alex T. Phythian-Adams2, Nina M. Rzechorzek2,3, David Hope-Jones2, Sorrel Cosens2, Stewart Jackson2, Matthew G. D. Bates2,4, David J. Collier5, David A. Hume6, Thomas Freeman6, A. A. Roger Thompson2,7, John Kenneth Baillie2,8,9

1 Royal Air Force Centre of Aviation Medicine, RAF Henlow, Beds, United Kingdom, 2 Apex (Altitude Physiology Expeditions), c/o Dr. J. K. Baillie, Critical Care Medicine, University of Edinburgh, Royal Infirmary of Edinburgh, United Kingdom, 3 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, 4 Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom, 5 William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 6 Division of Genetics and Genomics, Roslin Institute, Edinburgh, United Kingdom, 7 Academic Unit of Respiratory Medicine, Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom

Abstract

Acute mountain sickness (AMS) is a common problem among visitors at high altitude, and may progress to life-threatening pulmonary and cerebral oedema in a minority of cases. International consensus defines AMS as a constellation of subjective, non-specific symptoms. Specifically, headache, sleep disturbance, fatigue and dizziness are given equal diagnostic weighting. Different pathophysiological mechanisms are now thought to underlie headache and sleep disturbance during acute exposure to high altitude. Hence, these symptoms may not belong together as a single syndrome. Using a novel visual analogue scale (VAS), we sought to undertake a systematic exploration of the symptomatology of AMS using an unbiased, data-driven approach originally designed for analysis of gene expression. Symptom scores were collected from 292 subjects during 1110 subject-days at altitudes between 3650 m and 5200 m on Apex expeditions to Bolivia and Kilimanjaro. Three distinct patterns of symptoms were consistently identified. Although fatigue is a ubiquitous finding, sleep disturbance and headache are each commonly reported without the other. The commonest pattern of symptoms was sleep disturbance and fatigue, with little or no headache. In subjects reporting severe headache, 40% did not report sleep disturbance. Sleep disturbance correlates poorly with other symptoms of AMS (Mean Spearman correlation 0.25). These results challenge the accepted paradigm that AMS is a single disease process and describe at least two distinct syndromes following acute ascent to high altitude. This approach to analysing symptom patterns has potential utility in other clinical syndromes.

Introduction

Acute mountain sickness (AMS) occurs in up to 50% of individuals ascending to high altitude [1] and may progress to life-threatening pulmonary and cerebral oedema in a minority of cases [2]. The present international consensus defines AMS as a collection of subjective, non-specific symptoms [3]. Specifically, headache, sleep disturbance, and vague symptoms of fatigue and dizziness are given equal diagnostic weighting. Since we lack a common underlying mechanism to explain these symptoms, it is far from certain that they belong together as a single syndrome.

The most frequently-used criteria for the definition of AMS are based on the self-reported Lake Louise consensus scoring system (LLS) [3]. A positive Lake Louise Score can describe a spectrum of non-specific symptoms experienced on exposure to high altitude, and these may encompass more than one disease phenotype [4].

Headache is the cardinal feature of the LLS and is required under the present criteria for diagnosis of AMS [3]. There is evidence to suggest that the development of mild vasogenic cerebral oedema leading to increased intracranial pressure may be an important factor in the development of high altitude headache and AMS [5]. Optic nerve sheath diameter, an indirect measure of intracranial pressure, increases with altitude and also correlates with AMS score [6,7]. Several small case series in which participants were subjected to simulated high altitude before undergoing cerebral MRI also demonstrated an increase in brain volume [5,8]. A related hypothesis proposes that fluid redistribution to the intracellular space leading to astrocytic swelling underlies the development of symptomatic AMS [9]. More recently, it has been suggested that high altitude headache may relate to restricted venous drainage following the hypoxia-associated increase in cerebral blood flow at altitude [10].

In contrast, sleep disturbance at high altitude may be a mechanistically separate problem. Changes in the control of ventilation following acute ascent to altitude lead to a cyclical respiratory pattern. The hypoxic ventilatory drive causes hypo-capnia and a reduction in respiratory drive [11]. During sleep, in the absence of the wakefulness drive to breathing, hyperventilation
results in cyclical hypoxia and recurrent interruption of deep sleep stages [12].

As a categorical score, LLS is inherently disadvantaged in any attempt to quantify a continuous spectrum of disease severity. A further problem in the measurement of AMS is that LLS scores at high altitude produce a strongly skewed dataset, reducing the power of statistical analyses and making it difficult to quantitatively compare different symptoms, or to infer relationships between severity and other physiological or biochemical measurements.

A visual analogue scale (VAS) comprises a continuous horizontal line, each end of which is labelled by opposing statements (e.g. “no pain at all” and “unbearable pain”). Subjects specify the severity of a symptom by marking the line at a point between these two symptoms. This is then quantified by measuring the position of the marked point (in mm) on the line. Visual analogue scales have been rigorously validated as tools to quantify the severity of subjective symptoms, particularly in pain medicine [13–16], and are increasingly accepted for symptom scoring at high altitude [17]. Harris et al. used VAS scores as an endpoint in a randomised controlled trial comparing treatments of high altitude headache [18]. Since then, there have been four studies exploring the relationship between VAS and LLS describing altitude symptomatology [19–22], consistently demonstrating a correlation between LLS and VAS, both for individual components of LLS and overall LLS score. However, both the linearity of the relationship and the threshold VAS measurement for diagnosis of AMS are poorly defined. Unlike LLS, which is a standardised score and comparable across different studies, VAS studies have used different scales and as yet there is no consensus VAS for altitude illness.

We sought to perform an unbiased quantitative assessment of the symptomatology of AMS in healthy lowlanders acutely exposed to high altitude. We used a novel VAS questionnaire to record subjective symptoms experienced by research subjects over the course of 1110 subject-days at high altitude. Here we report the comparison between VAS and LLS, and apply a hypothesis-free clustering methodology widely used in transcriptomics [23] to identify different patterns of symptoms in individuals acutely exposed to high altitude.

Materials and Methods

Ethics Statement

The work reported here was approved by the Lothian Research Ethics Committee and the Tanzanian Institute for Medical Research. Written informed consent was obtained from all participants. The trial of antioxidant supplementation from which this study drew some data was registered at clinicaltrials.gov (NCT00664001).

Study Population

Data were collected from subjects at high altitude during two research expeditions. One hundred and three participants were recruited from the Apex 2 expedition to the Bolivian Andes [24–26]. Subjects flew to La Paz, Bolivia (3650 m) and after 4–5 days’ acclimatisation ascended over a period of 90 minutes to 5200 m by off-road vehicle. Forty one subjects were randomised to receive antioxidant supplements (1 g L-ascorbic acid, 400 IU alpha-tocopherol acetate, and 600 mg alpha-lipoic acid/day in four divided doses starting five days before ascent to 5200 m), 20 subjects were randomised to receive sildenafil (150 mg daily in three divided doses) and the remaining 42 received placebo only.

No subjects on the Apex 2 expedition took either acetazolamide or non-steroidal anti-inflammatory drugs (NSAIDs). Data were also included from 189 trekkers ascending to the Kibo Hut at 4730 m on Mt Kilimanjaro in Tanzania, as described elsewhere [27]. Of 189 subjects, 149 were attempting to summit via the standard Marangu route, which involves sleeping at huts located at 2743 m, 3760 m and 4730 m on the 5095 m summit attempt. Of these, 92 climbers had taken an additional rest day at 3760 m. The remaining 40 subjects were completing the Rongai route with no fixed sleeping points. These climbers were opportunistically sampled on the mountain, and as such we had no control over the medications used by the Kilimanjaro subjects.

Measurement of symptoms

Subjects were asked to complete a novel seven-question visual analogue scale (VAS) questionnaire during acute exposure to high altitude (conceived and designed by DJC), and provided in the Figure S1. This assesses five symptoms associated with high altitude: headache (“no headache at all” to “worst headache ever”), nausea (1. “I really want to be sick” to “don’t feel sick at all”; 2. “my guts are really bad” to “my guts are fine”), fatigue (1. “I’m totally exhausted” to “I’m full of energy”; 2. “I’m at my best” to “I’m at my worst”), dizziness (“no dizziness at all” to “more dizzy than ever”) and sleep quality (“worst night’s sleep ever” to “best night’s sleep ever”). Subjects were asked to mark their symptoms on a spectrum between the two extreme statements by marking their position on a horizontal 100 mm line. The direction of the scales (whether the direction from left-to-right corresponded to increasing or decreasing symptom severity) was deliberately reversed for some questions, but remained constant for each individual question over the course of the study. Questions were scored by measuring the distance from the low symptom severity end of the line, such that 0 mm corresponded to minimal severity and 100 mm to maximal severity for all seven questions. Summing the seven components produced a maximum total VAS score of 700 mm. The VAS included a quality control question, which asked with different wording about symptoms of fatigue in order to detect inattentive subjects. A minimum agreement of 40 mm was required between the responses to two questions (“I’m totally exhausted” to “I’m full of energy”, and “I’m at my best” to “I’m at my worst”).

Subjects also completed the Lake Louise Score (LLS) questionnaire, which includes assessment of headache, nausea and vomiting, fatigue/weakness, dizziness and sleep quality. Participants score the severity of each symptom from 0 (no symptom) to three (maximal severity); a total score of greater than or equal to three with the presence of headache equates to acute mountain sickness [3].

Sequential LLS and VAS data were collected daily from each of the 103 Apex 2 subjects over 11 days of exposure to high altitude (4 days at 3600 m, 7 days at 5200 m). Cross-sectional data from the 189 Kilimanjaro subjects were recorded at 4730 m during their ascent.

Data Analysis

VAS scores were measured by hand in mm. Groups of VAS questionnaire exhibiting similar symptom profiles were identified using a network analysis tool, BioLayout Express 3D, http://www.biolayout.org/ [28]. This software is primarily used to visualize and cluster networks from microarray expression data, in which the Pearson correlation coefficient is used as a measure of similarity between gene expression profiles to generate a network [29]. We created an undirected network, in which each node (depicted by coloured spheres in figures) represented one VAS questionnaire. Weighted edges (interconnecting lines) between these nodes represent Pearson correlation coefficients (r) between
A high correlation threshold of 0.95 was chosen in order to restrict the network analysis to relationships between very similar VAS questionnaires. VAS questionnaires with no connections above this correlation threshold are removed from the network.

The MCL algorithm was used to subdivide the network into discrete clusters of VAS questionnaires sharing similar features [30]. MCL provides a data-driven method to group similar VAS questionnaires with minimal input from the user, and hence minimal opportunity for unconsciously introducing bias. It is widely used for a variety of network clustering purposes, including the detection of protein families from similarity graphs [31], and inference of functional modules from protein-protein interactions [32] and gene expression data [29].

The MCL algorithm is described in considerable detail elsewhere, and we refer interested readers to the MCL website (http://micans.org/mcl) and the validation paper for further information [30]. Briefly, the algorithm simulates stochastic flow through the network, iteratively enhancing flow to well-connected nodes at the expense of poorly-connected nodes, until a stable state occurs in which inherent network structure is revealed. The granularity of the network (i.e. the size of individual clusters) is determined by the inflation value (MCLi), which was set for this analysis at 1.4.

The relationship between symptoms was explored by generating a correlation matrix in GraphPad Prism (version 6.01, GraphPad Software, CA) between VAS scores for each of five symptoms, and in Biolayout Express 3D. The correlation between VAS and LLS was explored using Spearman’s rank co-efficient, calculated in R 2.13.1 (R Foundation for Statistical Computing, Vienna, 2011) [33].

A simple graphical interface was developed (Excel 2003, Microsoft Corp, Redmond, WA), to allow exploration of the effects of changing the weighting given to each symptom recorded on the VAS score, the degree of concordance required between the to quality control questions and the effects of square-root normalization on the LLS and VAS data. The full dataset and formulae for data manipulation are provided as supplementary information at www.altitude.org/ams.php.

**Results**

Visual analogue scale (VAS) and Lake Louise Score (LLS) data were collected from 292 individuals over the course of 1110 subject-days at high altitude. This included 189 questionnaires from 189 subjects at the Kibo Hut (4730 m) on Mt Kilimanjaro and 921 questionnaires from 103 subjects on the Apex 2 expedition. From a possible 1133 subject-days on the Apex 2 expedition, data from 105 subject-days were lost as corresponding VAS and LLS were not available. Twenty-five subjects from Apex 2 were evacuated from 5200 m with severe acute mountain sickness. Questionnaires from these subjects were included only until time of evacuation resulting in the loss of 107 subject days. Sixty-five questionnaires (13 from Kilimanjaro, 52 from Apex 2, 5.9% of total questionnaires) were excluded as they did not meet the minimum agreement threshold of 40 mm between the two quality control questions on the VAS questionnaire. This left a total of 1045 subject-days at altitude (176 at Kilimanjaro, 869 on Apex 2), with both corresponding VAS and LLS data.
Cluster Analysis of AMS Symptoms

In order to maximise the power to detect different patterns of associated symptoms, we chose a composite analysis, including all questionnaires from within 1 week of a recent increase in altitude. This combined data from disparate sources, with differences in mode and rate of ascent, geographical location and drug treatment, and includes several questionnaires from the same volunteers at different times. The patterns reported here are consistently replicated in subsets of volunteers with same location and ascent rate, from the placebo group only and including only one questionnaire for each volunteer (Figure S2).

In order to explore different patterns of related symptoms, VAS data for the 1045 subjects-days at altitude were analysed in BioLayout Express 3D. The network generated was clustered using the MCL clustering algorithm (inflation value 1.4, minimum cluster size 30 nodes) producing three main clusters (Figure 1). The largest cluster contained 407 questionnaires, and corresponded to subjects who slept poorly, were fatigued, but had minimal headache or other symptoms. The second cluster of 127 questionnaires, contained subjects who reported poor sleep, headache, and fatigue. The third cluster contained 43 questionnaires and corresponded to subjects who had little sleep disturbance, but had headache and fatigue. The remaining questionnaires did not form a cluster large enough to be included in the analysis – the full dataset may be explored at www.altitude.org/ams.php.

Symptom Correlation

The relationship between different symptoms (rather than symptom profiles) was also investigated using the correlation between two symptoms across the whole population of responses from the Kilimanjaro expedition and the responses from Day 3 of the Apex expedition. There were no multiple measures taken from individual subjects. Symptoms recorded by the visual analogue scale inter-correlated as shown in Table 1. Sleep was most weakly correlated with the five other symptoms (mean correlation coefficient 0.25), whereas dizziness was most strongly correlated with the other reported symptoms (mean correlation co-efficient 0.44) (Figure 2).

There was no significant difference between clusters in the proportion of VAS responses from each of the Apex 2 treatment groups (placebo \( n = 42 \), antioxidant \( n = 41 \), sildenafil \( n = 20 \)). These data are shown in Table 2. Similarly, no relationship was seen between age or sex and any pattern of symptoms (Figure S3).

Timing of sleep assessment

For practical reasons, AMS questionnaires inquire about sleep quality on the night preceding the questionnaire. This is one reason why AMS scores are lower on the first day following acute ascent. However in physiological terms it is equally logical to assess sleep on the following night. This is particularly important when assessing the correlation of sleep with other symptoms, because the better sleep quality experienced on the night before ascent will cause an artefactual dissociation between sleep quality and the other symptoms of AMS.

Our dataset enables us to address the effect of this change. We repeated the correlation analyses on a subset of questionnaires in which we substituted the sleep score from the following day. For both the clustering of questionnaires with similar patterns of symptoms (Figure S2), and the correlation between the 5 symptoms across all volunteers, the patterns described above were consistently replicated.

Quantification of severity

Three hundred and eighty four of the 1045 questionnaires were consistent with a diagnosis of acute mountain sickness using the Lake Louise Score (LLS>2 with LLS headache>0). One subject developed high altitude pulmonary edema (HAPE) at 3600 m; there were no cases of HACE (high altitude cerebral edema). The median of all LLS scores was 2 (interquartile range 1–4). The mean total VAS was 192.6 mm with a standard deviation of 124.3 mm.

A square-root transformation resulted in normalisation of the VAS data (Kolmogorov-Smirnov test: KS distance 0.02036, \( P > 0.10 \)) but not the LLS data (Kolmogorov-Smirnov test: KS distance 0.1620, \( P < 0.0001 \)) (Figure 3).

Discussion and Conclusion

The scale of the dataset collated here, collected during 1110 subject-days at altitude, enables for the first time a comprehensive...
quantitative analysis of symptom correlation in altitude illness. We show that sleep disturbance is an outlier, correlating poorly with other symptoms of AMS. By identifying clusters sharing common patterns of symptoms, we demonstrate that distinct patterns of disease are primarily characterised by the presence of sleep disturbance or headache.

Among symptomatic individuals following acute ascent to high altitude, some degree of fatigue was a ubiquitous finding. In contrast, sleep disturbance and headache are each commonly reported without the other. This is consistent with the hypothesis that distinct pathogenetic mechanisms underlie sleep disturbance and headache at high altitude.

Analysis of correlation networks is a standard tool for drawing biological meaning from transcriptomic data [23,34,35]. As we demonstrate here, the same approach may also have substantial utility in classifying disease phenotypes. By providing an unbiased allocation of subjects with similar symptoms into clusters, it provides a novel and informative method for identifying patterns of disease. This method may easily be extended to other syndromes.

Our primary dataset contains repeated measures (1110 questionnaires obtained from 292 subjects), which may lead to a learning bias in subjects completing the VAS [21]. We also used symptom scores from some subjects who were taking oral antioxidant supplements or sildenafil for other trials. However these limitations do not affect the main outcomes. Repeat analyses

Table 2. The proportion of VAS responses from each treatment group in each of the symptom clusters.

<table>
<thead>
<tr>
<th></th>
<th>Cluster 1 (n = 407)</th>
<th>Cluster 2 (n = 127)</th>
<th>Cluster 3 (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (%)</td>
<td>130 (37.8%)</td>
<td>47 (40.9%)</td>
<td>17 (41.5%)</td>
</tr>
<tr>
<td>Antioxidant (%)</td>
<td>157 (45.6%)</td>
<td>38 (33.0%)</td>
<td>17 (41.5%)</td>
</tr>
<tr>
<td>Sildenafil (%)</td>
<td>57 (16.6%)</td>
<td>30 (26.1%)</td>
<td>7 (17.1%)</td>
</tr>
</tbody>
</table>

These differences are not statistically significant (Chi-squared test). doi:10.1371/journal.pone.0081229.t002

Figure 3. Frequency distribution of LLS and VAS scores (n = 1045). (A) Distribution of LLS. A positive LLS, indicating AMS, is a score of 3 or greater in the presence of headache; (B) Distribution of Lake Louise Scores following square-root transformation; (C) Distribution of total VAS scores (minimum 0 mm; maximum 700 mm); (D) Distribution of total VAS scores following square-root transformation of data. LLS: Lake Louise Score; VAS: visual analogue scale; AMS: acute mountain sickness. doi:10.1371/journal.pone.0081229.g003
focussing only on a single time point, or removing subjects on active drug treatments, did not affect the results and in these supplementary analyses the pattern of clustering was maintained (Figure S2).

Our study makes use of the largest VAS dataset to date to explore altitude-associated symptomatology, with 292 subjects and 1110 subject-days at altitude. As expected, there is a strong correlation between VAS and LLS [19–22]. Our work extends previous attempts to evaluate VAS scores by demonstrating the utility of VAS in creating a normally-distributed, continuous measure of AMS. VAS have a high test-retest reliability and inter-rater reliability [17] and may be more sensitive than discrete measures [36]. In future research using VAS as an endpoint or covariate, improved statistical power may be expected from the use of parametric tests that may only be applied to normally-distributed, continuous variables.

Furthermore, combining distinct pathophysiological processes into a single summary measure carries a risk of introducing excessive noise into studies of the pathogenesis of AMS, and of reducing the magnitude of effect signals in therapeutic studies. Focussing only on a group of well-correlated symptoms that share common mechanisms will further improve the quality of future research into AMS.

To be useful for clinical and physiological studies, a symptom score must accurately reflect the severity of a single clinical entity [37]. It is therefore critical that all of the symptoms included share an underlying pathogenesis. If not, effective treatments will be falsely rejected, and attempts to understand disease processes will be obstructed. It is our view that the results presented here should provoke a reassessment of consensus diagnostic criteria and severity measures for AMS.

Supporting Information

Figure S1 VAS questionnaire form. Questionnaire given to subjects to record VAS scores relating to symptoms experienced at altitude on the Apex 2 expedition. The same form was used by participants on the Kilimanjaro expedition. (TIF)

References


